Led by Oncology Sector, Life Sciences Deal Market Value Increases in 2017 Despite Downward Trend in Deal Volume
Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, has revealed that the market value of the most innovative and impactful global life sciences transactions of 2017 increased by 6% totaling US $364 billion, despite a decrease in overall deal volume. The transactions nominated for the annual Clarivate Cortellis Deal of the Year Awards include licensing and mergers and acquisitions. The announcement of the nominees at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco coincided with the Clarivate Deals and Portfolio Annual Review presentation – the foremost independent analysis of the economic trends shaping the life sciences sector in 2017.
Clarivate’s Deals and Portfolio Annual Review showcased a deep-dive analysis of 4,234 life sciences transactions. While overall the aggregate dollar value for deals increased from 2016, deal volume dropped by approximately 3% and saw contractions in almost every type of deal structure. This represents a reversal from last year when deal volume was up, but deal dollars were down.
“There is a healthy appetite for acquisitions and strong liquidity for deals in today’s market, but several factors contributed to deal volume falling below the last two years,” said Laura Vitez, commercial insights manager at Clarivate. “2017 saw a stronger IPO market for biopharma than the previous year, which meant companies had more viable alternatives to stay independent. We also experienced high valuations that resulted in heightened expectations during deal discussions. Finally, we saw many U.S. companies take a wait-and-see approach as the prospects for corporate tax reform played out right up to the end of the year.”
A total of ten Deal of the Year nominees was announced, five each in the categories of M&A and licensing. They include some of the industry’s most recognizable names (AstraZeneca, Celgene, and Merck) and life sciences upstarts like Rigontec, CureVac, and IFM Therapeutics. Nominees were recognized for innovations in creative deal structures, the use of novel technology, addressing unmet medical needs and new market penetrations. The analysis was drawn from the Cortellis suite of solutions from Clarivate Analytics. Industry participants may vote for the Deals of the Year at http://info.clarivate.com/DOTY. Winners will be announced in the beginning of February 2018.
Vitez added: “2018 shows promise for significant deal making, driven in large part by the lower corporate tax rates and tax repatriation allowances that were included in the final U.S. tax bill signed in December. U.S. biopharma companies comprise one-third of the top U.S. companies’ offshore cash holdings. When combined with the new lower corporate tax rates, we anticipate a considerable amount of the tax savings and repatriated cash will be used for M&A activities.”
This year’s Deals and Portfolio Review included a particularly deep investigation into oncology trends, which account for the largest number of M&A transactions by therapeutic area and the largest volume of licensing transactions. All but one of the top 20 dealmakers were active in oncology transactions last year.
“Oncology deals represented more than three times as many deals as neuroscience, the next most prevalent therapeutic area,” said Jaime Munro, global practice leader for portfolio and licensing at Clarivate. “Interestingly, we are seeing a trend of oncology deals focusing on earlier stages, with discovery and preclinical assets the focus of nearly two-thirds of oncology deals.”
2017 Deal of the Year nominees are:
Johnson & Johnson agreed to acquire Actelion in a $30 billion deal that is second in size only to the 2009 Roche/Genentech merger in pharma and biotech M&A. J&J gains the worldwide rights to ponesimod and cadazolid, while Actelion spins out its research and early-stage assets into a new company.
Bioverativ acquired True North, a private, clinical stage company focused on candidates for complement-mediated diseases, for $825 million total with $400 million upfront. This early acquisition, which included $425 million in milestones, strengthens innovation in a rare blood disease.
In a deal that had everything – a young firm, cool technology and a spinout – BMS acquired IFM for $2.32 billion, with $300 million upfront. The cancer sector deal includes $1.01 billion in milestones for IFM’s preclinical STING (simulator of interferon genes) and NLRP3 agonist programs.
Gilead acquired Kite, a developer of cell therapies for cancer treatment that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the cancer type. This transformative $11.9 billion deal brings immuno-oncology to the forefront at Gilead.
Merck acquired Rigontec, a University of Bonn spinout focused on developing retinotic acid-inducible gene 1 (RIG-1) targeting therapies for various tumors. The $552.3 million acquisition was a smartly structured early sale, and RIG-1 has potential with Merck’s Keytruda.
The companies entered into a $2.145 billion deal that included $45 million upfront, under which AstraZeneca would develop and commercialize inhaled respiratory drugs, including PRS-060, using Pieris's Anticalin platform for respiratory diseases. The transaction leverages a novel technological modality with multiple co-development opt-ins.
Celgene and BeiGene entered into a licensing agreement to develop and commercialize cancer drug BGB-A317 to combat solid tumors. The $1.292 billion deal includes $263 million in upfront cash and a $150 million equity stake. The deal is a win for both companies, as Celgene gets a PD-1 for its immuno-oncology backbone, while BeiGene gains an instant China portfolio.
This creatively structured $1.668 billion discovery stage licensing deal includes $40 million in upfront cash and $20 million in equity for the development of T-cell engaging bispecific antibodies against EGFR and certain immuno-oncology targets worldwide.
Eli Lilly licensed CureVac’s RNActive technology for the development and commercialization of up to five cancer vaccine products worldwide. A $1.803 billion deal with $50 million upfront and a $53 million equity stake, this is CureVac's largest collaboration to date, highlighting the industry's move toward targeting neoantigens.
Under this discovery stage deal, AbbVie will develop and commercialize Alector's immune therapies against Alzheimer’s disease and other neurodegenerative disorders worldwide. It works toward the promise of immuno-neurology by targeting microglia and macrophages – immune cells in the brain. The $225 million announcement includes $205 million upfront and $20 million in equity.
About Clarivate Analytics
Clarivate™ Analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.
Jason Milch, 312-379-9406
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet22.10.2018 20:15 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. The publication of the Phase 2 EQUATOR data also coincides with a plenary session presentation at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “These findings represent an important step forward in our efforts to improve outcomes for people livin
First Data Polska Deploys Inside Secure’s Mobile Payment Technology To Securely and Easily Connect to Mastercard and Visa22.10.2018 18:36 | Tiedote
Regulatory News: Inside Secure (Paris:INSD) (Euronext Paris: INSD), at the heart of security solutions for mobile and connected devices, today announced that First Data Polska S.A., a division of the global leader in commerce-enabling technology, selected Inside Secure technology to enable secure and flexible connections to Mastercard and Visa. First Data Polska S.A. chose Inside Secure’s Mobile Payment Client to easily integrate their solution with the Visa Token Service (VTS) and Mastercard Digital Enablement Service (MDES) – today’s major tokenization services that convert sensitive data into unique tokens that allow mobile payments to be processed. “Security and reliability are continual requirements for our services,” said Jolanta Rycerz, Member of Management Board at First Data Polska S.A. “We see Inside Secure as a valuable technology provider that enables us to easily migrate to the latest mobile payment technology and security standards. Thanks to Inside Secure, our customers,
PMI Launches Search for Next President and CEO22.10.2018 17:00 | Tiedote
Project Management Institute (PMI), the world’s leading professional membership organization for project managers, announced today that it has retained Heidrick & Struggles to help the organization find its next President and Chief Executive Officer (CEO). The dynamic leader shall oversee the implementation of a new strategic plan and guide the organization toward a future designed to help thousands of project professionals around the world accelerate their careers and make ideas a reality. Heidrick & Struggles is a premier provider of executive search, leadership assessment and development, organization and team effectiveness, and culture shaping services globally. PMI will conduct a comprehensive global review of both internal and external candidates for this key position. The selected candidate will embody PMI’s core values and possess the skillsets necessary to advance the organization’s key goals. PMI’s next President and CEO will help it execute a bold new multi-year initiative d
E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network22.10.2018 16:43 | Tiedote
E2open, the one place in the cloud to run your supply chain, today announced the acquisition of INTTRA, the leading ocean shipping network, software and information provider. The combination of INTTRA’s ocean carrier and shipper network with E2open’s industry leading business network will create a unified global logistics and supply chain network. E2open and INTTRA will join efforts to strengthen the connections and streamline the information flow between manufacturers, suppliers, shipping service providers, ocean carriers and all the participants in global trade. E2open is the largest cloud-based provider of networked supply chain solutions, featuring a complete portfolio of applications that enable the world’s most complex supply chains to better plan, collaborate, and execute their end-to-end operations. More than 70,000 partner companies and 200,000 users, many of the biggest brands and manufacturers across a range of industries, use the E2open network and platform to orchestrate t
Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease22.10.2018 15:00 | Tiedote
Raremark, the leading patient-data platform in rare disease, has raised £3m in funding from investors, led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and from existing major investor the Cass Entrepreneurship Fund. The funding will be used to develop Raremark’s patient-engagement and data-analysis technology, helping biopharmaceutical companies to identify, engage and learn from patients, accelerating the development of new treatments. Raremark’s platform is the foundation for building research networks of rare disease patients and their families. Raremark provides biopharmaceutical companies with access to anonymized and aggregated patient data, helping to reduce the time and cost of clinical development. The Raremark platform engages and retains patients, leveraging machine-learning technologies in novel ways. The approach is designed to raise health literacy and informed participation in medical research, to improve the quality of existing therapies and t
Celltrion Healthcare Hosts Forum with Patient Advocacy Groups to Provide Information on the Use of Biosimilars in Oncology22.10.2018 14:50 | Tiedote
To coincide with the ESMO 2018 Congress in Munich, Germany, Celltrion Healthcare invited perspective from experts including a physician and pharmacist to provide information to patient advocacy groups on the history of biosimilars, how they are tested and approved, their cost saving benefit and the wealth of clinical evidence already available on their use in order to improve understanding of biosimilars. The introduction of biosimilars in the treatment of cancer has the potential to reduce pressure on healthcare budgets and increase access to other innovative treatments or more potent regimens. This is achieved by offering more cost-effective alternatives to the reference medicinal products and by increasing competition in the market. Breast cancer is the most common cancer in women worldwide and accounts for a quarter of all cancer diagnoses in women.1 For the benefits of biosimilar use to be realised in oncology, and in the treatment of breast cancer, barriers to their uptake need t
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme